Loading...
•
Jun 30, 2023
GoodRx Q2 2023 Earnings Report
Second quarter financial results exceeded previously announced guidance.
Key Takeaways
GoodRx's second quarter 2023 results exceeded expectations, with revenue at $189.7 million. Prescription transactions revenue and volume returned to year-over-year growth. The company is focused on rebuilding momentum financially and operationally, aiming for growth in 2024 and beyond.
Total revenue of $189.7 million, exceeding previously announced guidance
Net income of $58.8 million with a net income margin of 31.0%
Adjusted EBITDA of $53.5 million with an Adjusted EBITDA Margin of 28.2%, exceeding previously announced guidance
Over 500,000 prescribers engaged with GoodRx through Provider Mode since its launch
Revenue by Segment
Forward Guidance
GoodRx is guiding to third quarter revenue in the range of $186 million to $190 million and Adjusted EBITDA Margin in the mid-to-high twenty-percent range. In the back half of this year, GoodRx will continue to balance business imperatives for 2024 and beyond with immediate results.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...